Remedium Research retatrutide 20mg

Remedium Research retatrutide

Remedium Research Retatrutide 20mg is a research grade peptide and is available in a prefilled pen format for in-vitro laboratory use. The most advanced triple hormone receptor agonist in clinical development is Retatrutide (research code LY3437943) and it is designed to activate GIP, GLP-1 and glucagon receptors at the same time. This receptor profile has made retatrutide a major focus of study in metabolic research, wizth phase 3 clinical trials currently underway to assess its impact on obesity, type 2 diabetes, knee osteoarthritis and obstructive sleep apnoea.

What Is Remedium Research – Mechanism of Action

Retatrutide is a 39 amino acid peptide engineered from a GIP backbone and conjugated to a C20 fatty di-acid moiety that allows albumin binding and extends its half-life to approximately 6 days. Retatrutide was 8.9 times more potent than human GIP at the GIP receptor, 2.5 times less potent than human GLP-1 at the GLP-1 receptor, and 2.9 times less potent than human glucagon at the glucagon receptor in vitro receptor profiling. Preclinical and early phase clinical data indicate that this triple activation could lead to food intake reduction, energy expenditure increase, lipid metabolism improvement and glucose homeostasis.

Remedium Retatrutide – Remedium Research Reta Pen

Analytical verification of purity

Each batch of Remedium Research Retatrutide 20mg is tested by Janoshik Analytical, an independent third-party peptide testing laboratory in the EU. The present batch of 20mg pen (RET-20-C-2604-001) was verified at 99.841% purity by HPLC, with a measured concentration of 22.51mg/mL and a task ID (150762) and verification key logged for direct cross-check against Janoshik’s server. This documentation standard is intended to exceed the usual purity standards of 95–99% of research grade.

Formatting and Handling

The prefilled pen format is designed with calibrated, click-indexed increments for protocol planning and does not require a reconstitution step as is needed with lyophilised vials. The 20mg pen delivers a sealed dose of balanced, stable pH solution. Store at 2-8°C protected from light. For best stability do not freeze.Remedium Research Retatrutide

Where To Buy Remedium Research Online – Remedium Reta 

Research Background

Retatrutide is not approved by the FDA or any other regulatory authority. It is an investigational molecule in phase 3 clinical development and the manufacturer has suggested plans to file for regulatory review in Q1 2027. The FDA said retatrutide is not an ingredient in any approved drug and can’t be compounded under federal law.

This product is for research use only. Not for use in diagnosis or therapy of humans or animals. Retatrutide is not an approved medicine in any jurisdiction. Remedium Research Retatrutide